{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T22:43:38Z","timestamp":1774478618351,"version":"3.50.1"},"reference-count":9,"publisher":"BMJ","issue":"7","license":[{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"unspecified","delay-in-days":19,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2022,7,9]]},"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:p>Although novel immunotherapy has shown promise for patients with melanoma, a more activated state of the immune system may lead to adverse systemic effects. Immunotherapy-induced meningoencephalitis is a rare and seldom reported adverse effect of immunotherapy but with the expanding role of immunotherapy in cancer treatments it must be recognised. Patients receiving immunotherapy should receive a proper warning about the potential for this life-threatening condition. Herein, we report a patient in his 70s with neurological changes after his second treatment with dual immunotherapy for a primary metastatic melanoma of the bladder neck.<\/jats:p>","DOI":"10.1136\/bcr-2022-249411","type":"journal-article","created":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T11:15:17Z","timestamp":1658315717000},"page":"e249411","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["Recognising immunotherapy-induced meningoencephalitis: a case during treatment for primary metastatic melanoma of the bladder neck"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8104-9679","authenticated-orcid":false,"given":"Joel","family":"Grunhut","sequence":"first","affiliation":[{"name":"Integrated Medical Science, Florida Atlantic University Charles E Schmidt College of Medicine, Boca Raton, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimron","family":"Brown","sequence":"additional","affiliation":[{"name":"Integrated Medical Science, Florida Atlantic University Charles E Schmidt College of Medicine, Boca Raton, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jose","family":"Lutzky","sequence":"additional","affiliation":[{"name":"Medical Oncology, Sylvester Comprehensive Cancer Center, Miami, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leor","family":"Skoczylas","sequence":"additional","affiliation":[{"name":"Integrated Medical Science, Florida Atlantic University Charles E Schmidt College of Medicine, Boca Raton, Florida, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2022,7,20]]},"reference":[{"key":"2025082623341672000_15.7.e249411.1","unstructured":"Key statistics for melanoma. American cancer Society., 2021. Available: https:\/\/www.cancer.org\/cancer\/melanoma-skin-cancer\/about\/key- statistics.html [Accessed 22 Nov 2021]."},{"key":"2025082623341672000_15.7.e249411.2","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study","volume":"35","author":"Hammers","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025082623341672000_15.7.e249411.3","doi-asserted-by":"publisher","DOI":"10.1080\/0284 186X.2020.1712473"},{"key":"2025082623341672000_15.7.e249411.4","doi-asserted-by":"crossref","DOI":"10.1177\/20420986211004745","article-title":"Immune checkpoint inhibitor-induced aseptic meningitis and encephalitis: a case-series and narrative review","volume":"12","author":"Thouvenin","year":"2021","journal-title":"Ther Adv Drug Saf"},{"key":"2025082623341672000_15.7.e249411.5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1703481"},{"key":"2025082623341672000_15.7.e249411.6","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/14740338.2020.1738382","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"19","author":"Haugh","year":"2020","journal-title":"Expert Opin Drug Saf"},{"key":"2025082623341672000_15.7.e249411.7","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1159\/000513001","article-title":"Immune-Related meningoencephalitis following nivolumab in metastatic renal cell carcinoma","volume":"14","author":"Shields","year":"2021","journal-title":"Case Rep Oncol"},{"key":"2025082623341672000_15.7.e249411.8","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2016-0487"},{"key":"2025082623341672000_15.7.e249411.9","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2022-249411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T06:34:28Z","timestamp":1756276468000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2022-249411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":9,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2022,7,20]]},"published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1136\/bcr-2022-249411"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2022-249411","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7]]}}}